Roche breast cancer drug gets FDA priority review (Reuters)
Reuters – Health regulators granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened.
Good Health is Your Greatest Wealth……Virgil
Reuters – Health regulators granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened.